Early prediction of blonanserin response in Japanese patients with schizophrenia

Taro Kishi, Yuki Matsuda, Kiyoshi Fujita, Nakao Iwata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Results: Thirty-seven patients were recruited (56.8% of them had first-episode schizophrenia), and 28 (75.7%) completed the trial. At week 8, blonanserin was associated with a significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score (P<0.0001) and in positive (P<0.0001), negative (P<0.0001), and general subscale scores (P<0.0001). In terms of percentage improvement of PANSS total scores from baseline to week 8, 64.9% of patients showed a ≥20% reduction in the PANSS total score and 48.6% showed a ≥30% reduction. However, 8.1% of patients experienced at least one adverse event. Using the 20% reduction in the PANSS total score at week 4 as a definition of an early response, the negative predictive values for later responses (ie, reductions of ≥30 and ≥40 in the PANSS total scores) were 88.9% and 94.1%, respectively. The specificities were 80.0% and 51.6%, respectively.

Conclusion: Our results suggest that the blonanserin response at week 4 could predict the later response at week 8.

Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia.

Methods: An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion criteria were antipsychotic naïve, and first-episode schizophrenia patients or schizophrenia patients with no consumption of any antipsychotic medication for more than 4 weeks before enrollment in this study. The positive predictive value, negative predictive value, sensitivity, specificity, and predictive power were calculated for the response status at week 4 to predict the subsequent response at week 8.

Original languageEnglish
Pages (from-to)1861-1866
Number of pages6
JournalNeuropsychiatric Disease and Treatment
Volume10
DOIs
Publication statusPublished - 23-09-2014

Fingerprint

Schizophrenia
Antipsychotic Agents
Korea
blonanserin
Japan
Clinical Trials
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{63955a55032d431bb8985e3221f8f358,
title = "Early prediction of blonanserin response in Japanese patients with schizophrenia",
abstract = "Results: Thirty-seven patients were recruited (56.8{\%} of them had first-episode schizophrenia), and 28 (75.7{\%}) completed the trial. At week 8, blonanserin was associated with a significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score (P<0.0001) and in positive (P<0.0001), negative (P<0.0001), and general subscale scores (P<0.0001). In terms of percentage improvement of PANSS total scores from baseline to week 8, 64.9{\%} of patients showed a ≥20{\%} reduction in the PANSS total score and 48.6{\%} showed a ≥30{\%} reduction. However, 8.1{\%} of patients experienced at least one adverse event. Using the 20{\%} reduction in the PANSS total score at week 4 as a definition of an early response, the negative predictive values for later responses (ie, reductions of ≥30 and ≥40 in the PANSS total scores) were 88.9{\%} and 94.1{\%}, respectively. The specificities were 80.0{\%} and 51.6{\%}, respectively.Conclusion: Our results suggest that the blonanserin response at week 4 could predict the later response at week 8.Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia.Methods: An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion criteria were antipsychotic na{\"i}ve, and first-episode schizophrenia patients or schizophrenia patients with no consumption of any antipsychotic medication for more than 4 weeks before enrollment in this study. The positive predictive value, negative predictive value, sensitivity, specificity, and predictive power were calculated for the response status at week 4 to predict the subsequent response at week 8.",
author = "Taro Kishi and Yuki Matsuda and Kiyoshi Fujita and Nakao Iwata",
year = "2014",
month = "9",
day = "23",
doi = "10.2147/NDT.S70227",
language = "English",
volume = "10",
pages = "1861--1866",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

Early prediction of blonanserin response in Japanese patients with schizophrenia. / Kishi, Taro; Matsuda, Yuki; Fujita, Kiyoshi; Iwata, Nakao.

In: Neuropsychiatric Disease and Treatment, Vol. 10, 23.09.2014, p. 1861-1866.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early prediction of blonanserin response in Japanese patients with schizophrenia

AU - Kishi, Taro

AU - Matsuda, Yuki

AU - Fujita, Kiyoshi

AU - Iwata, Nakao

PY - 2014/9/23

Y1 - 2014/9/23

N2 - Results: Thirty-seven patients were recruited (56.8% of them had first-episode schizophrenia), and 28 (75.7%) completed the trial. At week 8, blonanserin was associated with a significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score (P<0.0001) and in positive (P<0.0001), negative (P<0.0001), and general subscale scores (P<0.0001). In terms of percentage improvement of PANSS total scores from baseline to week 8, 64.9% of patients showed a ≥20% reduction in the PANSS total score and 48.6% showed a ≥30% reduction. However, 8.1% of patients experienced at least one adverse event. Using the 20% reduction in the PANSS total score at week 4 as a definition of an early response, the negative predictive values for later responses (ie, reductions of ≥30 and ≥40 in the PANSS total scores) were 88.9% and 94.1%, respectively. The specificities were 80.0% and 51.6%, respectively.Conclusion: Our results suggest that the blonanserin response at week 4 could predict the later response at week 8.Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia.Methods: An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion criteria were antipsychotic naïve, and first-episode schizophrenia patients or schizophrenia patients with no consumption of any antipsychotic medication for more than 4 weeks before enrollment in this study. The positive predictive value, negative predictive value, sensitivity, specificity, and predictive power were calculated for the response status at week 4 to predict the subsequent response at week 8.

AB - Results: Thirty-seven patients were recruited (56.8% of them had first-episode schizophrenia), and 28 (75.7%) completed the trial. At week 8, blonanserin was associated with a significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score (P<0.0001) and in positive (P<0.0001), negative (P<0.0001), and general subscale scores (P<0.0001). In terms of percentage improvement of PANSS total scores from baseline to week 8, 64.9% of patients showed a ≥20% reduction in the PANSS total score and 48.6% showed a ≥30% reduction. However, 8.1% of patients experienced at least one adverse event. Using the 20% reduction in the PANSS total score at week 4 as a definition of an early response, the negative predictive values for later responses (ie, reductions of ≥30 and ≥40 in the PANSS total scores) were 88.9% and 94.1%, respectively. The specificities were 80.0% and 51.6%, respectively.Conclusion: Our results suggest that the blonanserin response at week 4 could predict the later response at week 8.Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia.Methods: An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion criteria were antipsychotic naïve, and first-episode schizophrenia patients or schizophrenia patients with no consumption of any antipsychotic medication for more than 4 weeks before enrollment in this study. The positive predictive value, negative predictive value, sensitivity, specificity, and predictive power were calculated for the response status at week 4 to predict the subsequent response at week 8.

UR - http://www.scopus.com/inward/record.url?scp=84908218140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908218140&partnerID=8YFLogxK

U2 - 10.2147/NDT.S70227

DO - 10.2147/NDT.S70227

M3 - Article

AN - SCOPUS:84908218140

VL - 10

SP - 1861

EP - 1866

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -